의료기기 이야기

On 5 December 2023, the European Commission adopted an implementing act designating 5 EU reference laboratories (EURLs) in the field of in vitro diagnostic medical devices (IVDs). These EURLs will be involved in conformity assessment of high-risk (class D) IVDs as well as carry out certain advisory tasks. The designated EURLs together cover the following categories of class D IVDs: Hepatitis and..

MDCG에서 발행된 문서를 기반으로 제조업체와 유럽대리인을 대상으로 설문조사를 진행하고 있다. 관심이 있으신 업체의 경우에는 확인 바랍니다. ▶ 기간: 2024년 01월 15일까지 (CET 23:59:59 까지) EUSurvey - Survey (europa.eu) Study supporting the monitoring of availability of medical devices on the EU market Surveys for MD and IVD manufacturers and aut ec.europa.eu

[목적] A UDI-DI is to be assigned to a specific model of device and manufacturer. Contact lenses are available in many variants due to the high number of clinical parameters that characterise them. In accordance with Regulation (EU) 2017/745, an UDI-DI is to be assigned to each of such variants of contact lenses. This individualisation at UDI-DI level, that results in a proliferation of UDI-DIs to..

유럽연합에서 소프트웨어와 결합할 수 있는 하드웨어 또는 하드웨어 구성요성에 따라 규제사항의 적용 및 조항에 대한 가이던스를 발표하였다 (MDCG 2023-4). [소프트웨어 (MDSW)와 결합 가능한 하드웨어 조건 리스트] 1. A회사에서 생체신호를 획득하는 HW 또는 HW components를 만들고, 이와 연동이 되는 SW도 제작하는 경우 2. A회사에서 생체신호를 획득하는 HW 또는 HW components를 만들고, B회사에서 HW 또는 HW components와 연동이 되는 SW를 제작하는 경우 3. A회사에서 스마트폰 또는 웨어러블 디바이스를 통한 생체신호를 측정하여 SW에 전달되는 경우 4. A회사에서 스마트폰 또는 웨어러블 디바이스에서 측정된 생체신호를, B회사의 SW (App)에 전달되는..

Background In addition to all the regulatory expertise shared and exchanged, as well as the networking, one of the benefits to RAPS Convergence conferences are the impromptu discussions. It was during one of these instances at RAPS Convergence 2023 (in the Exhibit Hall) that we were conversing with a notified body representative, who shall remain unidentified. This notified body representative p..

The RAPS Convergence 2023 concluded on 5 October 2023. For a few glorious days, professionals convened in Montreal, Canada to discuss all aspects regulatory. One topic discussed extensively covered notified bodies and the European Medical Devices Regulation (2017/745, MDR). Notified bodies have been working to harmonize their activities. Notified body representatives have attended meetings and a..

유럽연합에서 MDR과 IVDR하에서 borderline에 있는 제품의 적용여부와 관련된 문서 개정하여 배포하였다. ▶ 개정일자: 2023년 09월 27일 ▶ Version. 3 ▶ MDR borderlines: medical devices and IVDs medical devices and medicinal products, including advanced therapy medicinal products (ATMPs) medical devices and biocides medical devices and substances of human origin medical devices and cosmetic products medical devices and food medical devices and pe..

▶ 유럽연합에서 MDR Annex XVI에 따른 의료목적이 없는 제품의 trasitional 에 따른 문의사항에 대해 Q&A 형식으로 제공 Q&A on transitional provisions for products without an intended medical purpose covered by annex XVI of the MDR (europa.eu) Q&A on transitional provisions for products without an intended medical purpose covered by annex XVI of the MDR Q&A on transitional provisions for products without an intended medical purpose cove..

Emergo by UL에서 EU MDR 관련 웨비나 예정 일자: 2023년 09월 26일 오전 9시~10시 (CDT, 한국시간 저녁 11시~12시) 주제: EU MDR PMS including PMCF and Vigilance EU MDR PMS Including PMCF and Vigilance | Emergo by UL EU MDR PMS Including PMCF and Vigilance In this complimentary webinar, our Emergo by UL subject matter expert will outline the latest insights about EU MDR PMS, including PMCF and vigilance. www.emergobyul.com

MDR 전환기간 동안 대상제품의 유럽시장 판매, 서비스 가능여부를 판단할 수 있는 흐름도 대상제품: Legacy device, Class III custom-made implantable devices 근거: Article 120 MDR, as ameded by Regulation 2023/607 Flowchart to assist in deciding whether or not a device is covered by the extended MDR transitional period (europa.eu) Flowchart to assist in deciding whether or not a device is covered by the extended MDR transitional period Flowc..